Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function Journal Article
| Authors: | Jain, N.; Zhao, Z.; Koche, R. P.; Antelope, C.; Gozlan, Y.; Montalbano, A.; Brocks, D.; Lopez, M.; Dobrin, A.; Shi, Y.; Gunset, G.; Giavridis, T.; Sadelain, M. |
| Article Title: | Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function |
| Abstract: | Suboptimal functional persistence limits the efficacy of adoptive T-cell therapies. CD28-based chimeric antigen receptors (CAR) impart potent effector function to T cells but with a limited lifespan. We show here that the genetic disruption of SUV39H1, which encodes a histone-3, lysine-9 methyl-transferase, enhances the early expansion, long-term persistence, and overall antitumor efficacy of human CAR T cells in leukemia and prostate cancer models. Persisting SUV39H1-edited CAR T cells demonstrate improved expansion and tumor rejection upon multiple rechallenges. Transcriptional and genome accessibility profiling of repeatedly challenged CAR T cells shows improved expression and accessibility of memory transcription factors in SUV39H1-edited CAR T cells. SUV39H1 editing also reduces expression of inhibitory receptors and limits exhaustion in CAR T cells that have undergone multiple rechallenges. Our findings thus demonstrate the potential of epigenetic programming of CAR T cells to balance their function and persistence for improved adoptive cell therapies. SIGNIFICANCE: T cells engineered with CD28-based CARs possess robust effector function and antigen sensitivity but are hampered by limited persistence, which may result in tumor relapse. We report an epigenetic strategy involving disruption of the SUV39H1-mediated histone-silencing program that promotes the functional persistence of CD28-based CAR T cells. See related article by López-Cobo et al., p. 120. This article is featured in Selected Articles from This Issue, p. 5. ©2023 American Association for Cancer Research. |
| Keywords: | leukemia; methylation; genetics; t lymphocyte; t-lymphocytes; metabolism; drug screening; xenograft model antitumor assays; methyltransferase; methyltransferases; receptors, antigen, t-cell; histone; chimeric antigen receptor; repressor protein; repressor proteins; histones; adoptive immunotherapy; immunotherapy, adoptive; lymphocyte antigen receptor; cd28 antigen; humans; human; male; receptors, chimeric antigen; cd28 antigens; suv39h1 protein, human |
| Journal Title: | Cancer Discovery |
| Volume: | 14 |
| Issue: | 1 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2024-01-01 |
| Start Page: | 142 |
| End Page: | 157 |
| Language: | English |
| DOI: | 10.1158/2159-8290.CD-RW2023-178 |
| PUBMED: | 37934007 |
| PROVIDER: | scopus |
| PMCID: | PMC10880746 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Michel Sadelain -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work